Open an account

Transmedics Group

TMDX · NASDAQ

$74.75+$3.15 (+4.40%)TodayMarket closed ·
Prev close $71.60

About TMDX

TransMedics Group, Inc. operates as a commercial stage medical technology company. The company is headquartered in Andover, Massachusetts and currently employs 898 full-time employees. The company went IPO on 2019-05-02. The firm specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Its Organ Care System (OCS) is a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside the human body. The company also developed its National OCS Program (NOP), which is a turnkey solution to provide outsourced organ procurement, OCS perfusion management and transplant logistics services, to provide transplant programs in the United States. Its logistics services include aviation transportation and other coordination activities. Its NOP provides trained organ procurement surgeons, clinical specialists and transplant coordinators that provide an end-to-end clinical solution using its OCS technology.

Employees
898
Headquarters
Andover, Massachusetts
Listed
May 2, 2019
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
transmedics.com

TMDX key statistics

Market cap
2.59B
Price-earnings ratio
18.55
Dividend yield
—
Average volume
793.35K
Volume
1.17M
Open price
$71.65
High today
$75.66
Low today
$67.31
52 Week high
$156.00
52 Week low
$60.11

Transmedics Group (TMDX) at a glance

Transmedics Group (TMDX) last traded at $74.75, with a market cap of 2.59B and a price-to-earnings ratio of 18.55.

Today the stock has traded between $67.31 and $75.66. The current price is 11.1% above the day's low and 1.2% below its high.

Volume so far is 1.17M shares, above the average of 793.35K shares a day.

Over the past year Transmedics Group has ranged from $60.11 to $156.00, and now sits 15% of the way up that range.

Transmedics Group met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported $0.44 per share against an estimate of $0.4828.

The average analyst price target is $105.06, 40.5% above the current price, from 13 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

62%of 13 analyst ratings say Buy
  • Buy61.5%
  • Hold38.5%
  • Sell0.0%
Price target · 13 analystsAvg $105.06
Low
$65.65
Now
$74.75
High
$141.75

TMDX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 80.2% on average.

  1. Q3 FY24: reported $0.12 per share against an estimate of $0.299
  2. Q4 FY24: reported $0.19 per share against an estimate of $0.1632
  3. Q1 FY25: reported $0.70 per share against an estimate of $0.2618
  4. Q2 FY25: reported $0.92 per share against an estimate of $0.4599
  5. Q3 FY25: reported $0.66 per share against an estimate of $0.3579
  6. Q4 FY25: reported $0.53 per share against an estimate of $0.3987
  7. Q1 FY26: reported $0.30 per share against an estimate of $0.625
  8. Q2 FY26: reported $0.44 per share against an estimate of $0.4828

TMDX news

  • Press releasePRNewswire

    Did TransMedics Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

  • Press releaseBusiness Wire

    TransMedics Group Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of TransMedics Group, Inc. - TMDX

  • Press releasePRNewswire

    TransMedics Appoints Fernando Araujo as Chief Financial Officer and Reiterates 2026 Financial Outlook

  • Press releasePRNewswire

    Did TransMedics Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

  • Press releasePRNewswire

    Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. - TMDX

  • Press releasePRNewswire

    TransMedics to Present at Upcoming September Investor Conferences

  • Press releaseGlobe Newswire

    TransMedics Group, Inc. Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. – TMDX

  • Press releasePRNewswire

    TransMedics Group Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of TransMedics Group, Inc. - TMDX

Similar companies

Companies in the same industry as Transmedics Group

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.